Pfizer/BioNTech on Friday applied to the European Medicines Agency, EU’s drug regulatory authority, for emergency use approval for its COVID-19 vaccine in children aged 12 to 15.

“This submission is based on data from a pivotal Phase 3 clinical trial, which enrolled 2,260 participants aged 12 to 15 years,” said a statement from the pharma companies.

“Topline results from this trial, announced on March 31, 2021, showed a vaccine efficacy of 100% in participants with or without prior SARS-CoV-2 infection and robust antibody responses,” it added.

The companies previously applied to the US Food and Drug Administration (FDA) for emergency use authorization.

Copyright 2022 Anadolu Agency. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.